Biological basis of immunomodulatory preparations using in treatment of multiple myeloma
Immunomodulatory preparations (IMP) — lenalidomide (СС-5013, Revlimid®) and pomlidomide (CC-4047, Actimid®) — a new class of the medical products which are thalidomide synthetic derivatives. In comparison with initial compound they possess higher therapeutic activity and the optimized profile of tox...
Saved in:
Main Author: | S. V. Semochkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-11-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/623 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01) -
Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01) -
Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01) -
Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)